Andrea Brunoro
Research Subjects
Andrea Brunoro has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Gianluca Scuderi
Ophthalmology Unit, Neurosciences, Mental Health, and Sensory Organs (NESMOS) Department, Sapienza University of Rome, Rome, Italy
2 shared publications - Maurizio Battaglia Parodi
Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 shared publications - Aldo Caporossi
Ophthalmology Unit, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy., Largo F. Vito 1, 00168 Rome, Italy
1 shared publication Alessandro Arrigo
1 shared publication- Bianca Maria Piraccini
Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine University of Bologna Bologna Italy
1 shared publication Bizzarri Stefania
Villa Alba Rome Italy
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (1) , e70532
A Real‐Life Assessment of Injectable Polynucleotides High Purification Technology in Aesthetic Medicine for Skin Rejuvenation
Background: Polynucleotides (PN) are innovative polymers that improve skin hydration and elasticity, serving as alternatives to traditional dermal fillers. Medical devices based on PN High Purification Technology (PN HPT) represent a new generation of injectable products designed to restore hydration, elasticity, and overall tissue quality. PN HPT is known for its clinical versatility and excellent tolerability. Aims: To assess the real‐world performance and safety of Plinest (40 mg/2 mL of PN HPT in a 2 mL pre‐filled syringe), a CE‐marked class III medical device for skin rejuvenation of the face, neck, and décolleté. Methods: This observational clinical data collection involved 66 adult patients, each of whom could receive treatment in up to three areas (face, neck, décolleté). Patients underwent three sessions of intradermal PN HPT injections. A total of 106 questionnaires were collected: 47 for the face, 33 for the neck, and 26 for the décolleté. Performance was evaluated using the Global Clinical Improvement Scale (GCI‐S) and Global Aesthetic Improvement Scale (GAIS). Safety was monitored through spontaneous adverse event (AE) reporting. Results: Clinician‐reported outcomes showed visible improvement in 100% of facial treatments, with 53.5% rated as “marked” or “excellent.” In the neck and décolleté areas, moderate to significant improvements were observed in over 93% and 88% of cases, respectively. Patient satisfaction ranged from 97% to 100%. No serious AEs occurred. Conclusions: PN HPT demonstrated a favorable tolerability and performance profile in real‐life aesthetic practice, supporting its role in improving skin quality and reducing signs of aging.
- 2 January 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (1) , e70532
Open AccessA Real‐Life Assessment of Injectable Polynucleotides High Purification Technology in Aesthetic Medicine for Skin Rejuvenation
Background: Polynucleotides (PN) are innovative polymers that improve skin hydration and elasticity, serving as alternatives to traditional dermal fillers. Medical devices based on PN High Purification Technology (PN HPT) represent a new generation of injectable products designed to restore hydration, elasticity, and overall tissue quality. PN HPT is known for its clinical versatility and excellent tolerability. Aims: To assess the real‐world performance and safety of Plinest (40 mg/2 mL of PN HPT in a 2 mL pre‐filled syringe), a CE‐marked class III medical device for skin rejuvenation of the face, neck, and décolleté. Methods: This observational clinical data collection involved 66 adult patients, each of whom could receive treatment in up to three areas (face, neck, décolleté). Patients underwent three sessions of intradermal PN HPT injections. A total of 106 questionnaires were collected: 47 for the face, 33 for the neck, and 26 for the décolleté. Performance was evaluated using the Global Clinical Improvement Scale (GCI‐S) and Global Aesthetic Improvement Scale (GAIS). Safety was monitored through spontaneous adverse event (AE) reporting. Results: Clinician‐reported outcomes showed visible improvement in 100% of facial treatments, with 53.5% rated as “marked” or “excellent.” In the neck and décolleté areas, moderate to significant improvements were observed in over 93% and 88% of cases, respectively. Patient satisfaction ranged from 97% to 100%. No serious AEs occurred. Conclusions: PN HPT demonstrated a favorable tolerability and performance profile in real‐life aesthetic practice, supporting its role in improving skin quality and reducing signs of aging.
- Open Access
- 17 January 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (S265)
Fight the silent thief of sight: glaucoma incidence in citizens of Sassari
Purpose: To identify the silent thief of sight in asymptomatic citizens of Sassari and assess the importance of the screening in glaucoma.Methods: Seven ophthalmologists performed free specialist examinations and included 322 asymptomatic subjects from 40 to 80 years. All volunteers attended the screening with assessment of intraocular pressure (IOP, air‐puff tonometer TX‐f Canon) and optic disc evaluation by fundus biomicroscopy. Subjects with optic nerve cupping underwent retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness examination (i‐Vue OptoVue OCT).Results: Subjects with a diagnosis of hypertension or treated for glaucoma were excluded. Of the total 322 volunteers included, 23.6% had glaucoma familiarity, 8.7% declared that the screening was the first ophthalmological visit and 55,28% stated that they had never been examined with tonometry before. IOP was >21 mmHg in the 7% and optic disc showed abnormal cupping in 6.8% of the volunteers. The 2.48% of the subjects had both ocular hypertension (IOP>21 mmHg) and papillary abnormalities, and 7.4% of the 27 OCT performed showed anomalies.Conclusions: Glaucoma is one of the leading causes of irreversible blindness, but early detection and treatment could prevent severe vision loss. For these reasons, glaucoma screenings are fundamental even though they could have limited diagnostic power. In fact, subjects with OCT anomalies were directed to further examinations. The results of this screening are quite impressive, most of all the 8% of patients declaring that they had never underwent an ophthalmological visit and the 55% of patient that undertake a tonometry for the first time. The discrepancy between these data stresses the importance of a regular ophthalmological examination that is still confused with the visual acuity assessment made by opticians. Only a complete ophthalmological visit can diagnose conditions affecting irreversibly the vision, such as the silent thief of sight.
- 17 January 2021
- Published by Wiley in Acta Ophthalmologica
- Vol. 99 (S265)
Open AccessFight the silent thief of sight: glaucoma incidence in citizens of Sassari
Purpose: To identify the silent thief of sight in asymptomatic citizens of Sassari and assess the importance of the screening in glaucoma.Methods: Seven ophthalmologists performed free specialist examinations and included 322 asymptomatic subjects from 40 to 80 years. All volunteers attended the screening with assessment of intraocular pressure (IOP, air‐puff tonometer TX‐f Canon) and optic disc evaluation by fundus biomicroscopy. Subjects with optic nerve cupping underwent retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness examination (i‐Vue OptoVue OCT).Results: Subjects with a diagnosis of hypertension or treated for glaucoma were excluded. Of the total 322 volunteers included, 23.6% had glaucoma familiarity, 8.7% declared that the screening was the first ophthalmological visit and 55,28% stated that they had never been examined with tonometry before. IOP was >21 mmHg in the 7% and optic disc showed abnormal cupping in 6.8% of the volunteers. The 2.48% of the subjects had both ocular hypertension (IOP>21 mmHg) and papillary abnormalities, and 7.4% of the 27 OCT performed showed anomalies.Conclusions: Glaucoma is one of the leading causes of irreversible blindness, but early detection and treatment could prevent severe vision loss. For these reasons, glaucoma screenings are fundamental even though they could have limited diagnostic power. In fact, subjects with OCT anomalies were directed to further examinations. The results of this screening are quite impressive, most of all the 8% of patients declaring that they had never underwent an ophthalmological visit and the 55% of patient that undertake a tonometry for the first time. The discrepancy between these data stresses the importance of a regular ophthalmological examination that is still confused with the visual acuity assessment made by opticians. Only a complete ophthalmological visit can diagnose conditions affecting irreversibly the vision, such as the silent thief of sight.
- 24 April 2020
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 30 (4) , 780-794
Benefits of micronutrient supplementation for reducing the risk of wet age-related macular disease and diabetic retinopathy
Age-related macular disease and diabetic retinopathy are chronic degenerative diseases characterised by progressive visual impairment. In Europe, age-related macular disease accounts for over 15% of blindness in adults over 50 years of age, and although the burden of diabetic retinopathy in terms of vision impairment is lower, vision loss associated with diabetic retinopathy is increasing with the rising prevalence of diabetes mellitus and the ageing of the population. Late-stage age-related macular disease can be subdivided into dry (non-neovascular) or wet (neovascular or exudative) forms. The large Age-Related Eye Disease Study 2 showed that supplementation with antioxidant nutrients reduces choroids neovascularisation and reduces the risk of progression of neovascular age-related macular disease. Antioxidant micronutrient supplements have also shown promising results in preventing the pathogenesis of retinopathy in animal models of diabetes. Age-related macular disease and diabetic retinopathy are understood to share some common pathophysiological characteristics, suggesting that micronutrients have an important role in ocular health in both conditions. This article will review the current evidence for the utility of micronutrients in preventing the development and progression of neovascular age-related macular disease and diabetic retinopathy.
- 24 April 2020
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 30 (4) , 780-794
Benefits of micronutrient supplementation for reducing the risk of wet age-related macular disease and diabetic retinopathy
Age-related macular disease and diabetic retinopathy are chronic degenerative diseases characterised by progressive visual impairment. In Europe, age-related macular disease accounts for over 15% of blindness in adults over 50 years of age, and although the burden of diabetic retinopathy in terms of vision impairment is lower, vision loss associated with diabetic retinopathy is increasing with the rising prevalence of diabetes mellitus and the ageing of the population. Late-stage age-related macular disease can be subdivided into dry (non-neovascular) or wet (neovascular or exudative) forms. The large Age-Related Eye Disease Study 2 showed that supplementation with antioxidant nutrients reduces choroids neovascularisation and reduces the risk of progression of neovascular age-related macular disease. Antioxidant micronutrient supplements have also shown promising results in preventing the pathogenesis of retinopathy in animal models of diabetes. Age-related macular disease and diabetic retinopathy are understood to share some common pathophysiological characteristics, suggesting that micronutrients have an important role in ocular health in both conditions. This article will review the current evidence for the utility of micronutrients in preventing the development and progression of neovascular age-related macular disease and diabetic retinopathy.
- Open Access
Cytidine 5′-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma
Glaucoma, a heterogeneous set of progressively degenerative optic neuropathies characterized by a loss of retinal ganglion cells (RGCs) and typical visual field deficits that can progress to blindness, is a neurodegenerative disease involving both ocular and visual brain structures. Although elevated intraocular pressure (IOP) remains the most important modifiable risk factor of primary open-angle glaucoma (POAG) and is the main therapeutic target in treating glaucoma, other factors that influence the disease course are involved and reaching the optimal IOP target does not stop the progression of glaucoma, as the visual field continues to narrow. In addition to a managed IOP, neuroprotection may be beneficial by slowing the progression of glaucoma and improving the visual defects. Citicoline (cytidine 5′-diphosphocholine) is a naturally occurring endogenous compound that has been investigated as a novel therapeutic agent for the management of glaucoma. Citicoline has demonstrated activity in a range of central neurodegenerative diseases, and experimental evidence suggests a it performs a neuromodulator and neuroprotective role on neuronal cells, including RGCs, associated with improvement in visual function, extension of the visual field and central benefits for the patient. This review aims to critically summarize the current evidence for the neuroprotective properties of citicoline in glaucoma.
Open AccessCytidine 5′-Diphosphocholine (Citicoline): Evidence for a Neuroprotective Role in Glaucoma
Glaucoma, a heterogeneous set of progressively degenerative optic neuropathies characterized by a loss of retinal ganglion cells (RGCs) and typical visual field deficits that can progress to blindness, is a neurodegenerative disease involving both ocular and visual brain structures. Although elevated intraocular pressure (IOP) remains the most important modifiable risk factor of primary open-angle glaucoma (POAG) and is the main therapeutic target in treating glaucoma, other factors that influence the disease course are involved and reaching the optimal IOP target does not stop the progression of glaucoma, as the visual field continues to narrow. In addition to a managed IOP, neuroprotection may be beneficial by slowing the progression of glaucoma and improving the visual defects. Citicoline (cytidine 5′-diphosphocholine) is a naturally occurring endogenous compound that has been investigated as a novel therapeutic agent for the management of glaucoma. Citicoline has demonstrated activity in a range of central neurodegenerative diseases, and experimental evidence suggests a it performs a neuromodulator and neuroprotective role on neuronal cells, including RGCs, associated with improvement in visual function, extension of the visual field and central benefits for the patient. This review aims to critically summarize the current evidence for the neuroprotective properties of citicoline in glaucoma.
- Open Access
- 1 January 2018
- Published by Touch Medical Media, Ltd. in European Ophthalmic Review
- Vol. 12 (1)
Micronutrients and Benefits of Supplementation for Reducing the Risk of Progression of Age-related Macular Degeneration – An Update
Age-related macular degeneration (AMD) is a chronic, progressive degenerative disease with subsequent reduction in visual acuity.
- 1 January 2018
- Published by Touch Medical Media, Ltd. in European Ophthalmic Review
- Vol. 12 (1)
Open AccessMicronutrients and Benefits of Supplementation for Reducing the Risk of Progression of Age-related Macular Degeneration – An Update
Age-related macular degeneration (AMD) is a chronic, progressive degenerative disease with subsequent reduction in visual acuity.
Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification
Summary: The prevalence of onychomycosis differs according to geographic area and over time and is influenced by several factors. The epidemiology of onychomycosis in Italy is still unclear. To evaluate the prevalence of onychomycosis in a representative sample of the Italian population a group of Dermatologists and General Practitioners carried out an observational survey on the patients coming to their office during a 1‐month period. Any patient with skin or systemic disease giving their consent was enrolled. Demographic characteristics, comorbidities, lifestyles, history of previous mycosis, clinical aspects of onychomycosis and mycological evaluation were studied. A total of 8331 patients (56.7% female and 43.3% male) were evaluated. More than half of them were aged ≥46 years. Onychomycosis was diagnosed in 14.2% of patients. Big toe and thumb were the most frequently affected nails. Onychomycosis was moderate‐severe in 74.1% of the cases. Mycological tests were positive in 81.3% of the cases. Dermatophytes were found in 76.6% of the cases, yeasts in 17.2% and moulds in 6.3%. Risk factors and/or comorbidities were present in 68.2% of the cases. This survey showed a 14% prevalence of onychomycosis in the evaluated population. The main risk factors were previous onychomycosis, diabetes, hallux valgus and use of occlusive footwear.
Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification
Summary: The prevalence of onychomycosis differs according to geographic area and over time and is influenced by several factors. The epidemiology of onychomycosis in Italy is still unclear. To evaluate the prevalence of onychomycosis in a representative sample of the Italian population a group of Dermatologists and General Practitioners carried out an observational survey on the patients coming to their office during a 1‐month period. Any patient with skin or systemic disease giving their consent was enrolled. Demographic characteristics, comorbidities, lifestyles, history of previous mycosis, clinical aspects of onychomycosis and mycological evaluation were studied. A total of 8331 patients (56.7% female and 43.3% male) were evaluated. More than half of them were aged ≥46 years. Onychomycosis was diagnosed in 14.2% of patients. Big toe and thumb were the most frequently affected nails. Onychomycosis was moderate‐severe in 74.1% of the cases. Mycological tests were positive in 81.3% of the cases. Dermatophytes were found in 76.6% of the cases, yeasts in 17.2% and moulds in 6.3%. Risk factors and/or comorbidities were present in 68.2% of the cases. This survey showed a 14% prevalence of onychomycosis in the evaluated population. The main risk factors were previous onychomycosis, diabetes, hallux valgus and use of occlusive footwear.